The USFDA has approved the first and only non-immunosuppressant, sparsentan , for immunoglobulin A nephropathy (IgAN). It is a once-daily oral medication to reduce proteinuria in adults with IgAN. Interim results from ongoing PROTECT Study The accelerated approval of sparsentan is based on the interim primary endpoints from an ongoing phase III trial.
What treatment would you recommend to patients with IgA nephropathy? Share your views by commenting below! ##Source##FDA##
